Brawn Laboratories Limited

Brawn Laboratories Limited, established on March 27, 1990, is a public limited company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U73200DL1990PLC039653. As of the latest available data, Brawn Laboratories has an authorized capital of ₹10 million and a paid-up capital of ₹9.95 million. The company operates in the pharmaceutical sector, focusing on the manufacture and export of finished pharmaceutical formulations. Brawn Laboratories has a significant presence in over 60 countries, including regions such as Southeast Asia, Latin America, Africa, the Middle East, and the Commonwealth of Independent States (CIS).

Brawn Laboratories operates a state-of-the-art manufacturing facility located in Faridabad, approximately 30 kilometers from New Delhi. The plant spans over 125,000 square feet and is equipped with three separate blocks dedicated to the production of non-beta, cephalosporin, and penicillin products. This setup enables the company to manufacture a wide range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility adheres to Good Manufacturing Practices (GMP) and holds ISO 9001:2008 certification, ensuring high-quality production standards.

The leadership team at Brawn Laboratories Limited comprises several key individuals:

• Brij Raj Gupta: Chairman & Managing Director, appointed on April 23, 2003.

• Adarsh Kumar Gupta: Director, appointed on April 23, 2001.

• Love Gupta: Director, appointed on October 5, 2010.

• Bal Kishan Sharma: Director, appointed on March 28, 2015.

• Rajveer Singh: Director, appointed on October 5, 2010.

• Rakesh Kumar Dhama: Director, appointed on October 5, 2010.

• Nanak Singh Rana: Director, appointed on September 30, 2014.

• Urmila Gupta: Director, appointed on April 28, 2006.

• Brij Bala Gupta: Director, appointed on October 3, 2003.

• Trilok Singh: Director, appointed on March 28, 2015.

• Ashish Yadav Kumar: Director, appointed on July 16, 2018.

These individuals collectively guide the strategic direction and operations of Brawn Laboratories Limited.

Brawn Laboratories Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, facilitating market access and distribution. Brawn Laboratories has been awarded WHO-GMP and ISO 9001:2008 certifications, which are recognized internationally and support its entry into these regulated markets. The company's adherence to international quality standards enhances its credibility and acceptance in these markets.

Brawn Laboratories Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has established its own offices in countries such as Vietnam, Philippines, Myanmar, Ethiopia, and Congo, with plans to inaugurate an office in Panama. This strategic expansion enables Brawn Laboratories to strengthen its relationships with local partners and navigate the regulatory landscapes of these regions effectively. The company's commitment to long-term business relationships facilitates a deeper understanding of local market dynamics and consumer needs.

Brawn Laboratories Limited has adopted a diversified geographic strategy, establishing a presence in over 60 countries across multiple continents. This broad geographic footprint mitigates concentration risk and allows the company to tap into various markets with differing economic cycles and regulatory environments. The company's expansion into emerging markets, coupled with its presence in regulated markets, reflects a strategic direction aimed at achieving balanced growth and global reach.

Brawn Laboratories Limited has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), enabling the export of its pharmaceutical products to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for several of its products, seeking approval for marketing in the U.S. market. Brawn Laboratories has also submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facility has undergone FDA inspections, and it has received Establishment Inspection Reports (EIRs) indicating compliance with FDA regulations. These actions demonstrate Brawn Laboratories' commitment to meeting the stringent requirements of the U.S. pharmaceutical market.

Brawn Laboratories Limited holds Good Manufacturing Practices (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications affirm the company's adherence to international quality standards in the manufacturing of pharmaceutical products. The WHO-GMP certification is particularly significant for accessing markets in developing countries, as it is recognized by the World Health Organization. The EU GMP certification facilitates the company's entry into European markets, ensuring that its products meet the rigorous quality standards required by EU regulations.

In India, Brawn Laboratories Limited operates under the regulations of the Central Drugs Standard Control Organisation (CDSCO). The company holds manufacturing licenses issued by the CDSCO, authorizing it to produce pharmaceutical formulations for both domestic and export markets. Brawn Laboratories complies with the requirements set forth by the CDSCO and state drug controllers, ensuring the safety, efficacy, and quality of its products. The company also obtains No Objection Certificates (NOCs) for exports, facilitating the international distribution of its products.

As of March 28, 2026, there are no publicly available records indicating that Brawn Laboratories Limited has received Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA. The company's adherence to international quality standards and regulatory requirements suggests a proactive approach to compliance and quality assurance.

Brawn Laboratories Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic pharmaceutical segment, competitors include companies like Laurus Labs, Symbiotec, and SeQuent. In the branded pharmaceutical segment, the company competes with established players in various therapeutic categories. Brawn Laboratories differentiates itself through its extensive product portfolio, international certifications, and a strong presence in emerging markets. The company's focus on quality manufacturing and regulatory compliance enhances its competitiveness in the global market.

Brawn Laboratories Limited's key differentiators include its comprehensive product portfolio covering a wide range of therapeutic segments, adherence to international quality standards such as WHO-GMP and ISO 9001:2008 certifications, and a diversified geographic presence across over 60 countries. The company's state-of-the-art manufacturing facility in Faridabad, equipped with advanced technology and dedicated production blocks, further distinguishes it in the industry. Additionally, Brawn Laboratories' commitment to long-term business relationships and its proactive approach to regulatory compliance contribute to its unique position in the market.

Brawn Laboratories Limited's current strategic direction focuses on expanding its global footprint by entering both regulated and emerging markets. The company's adherence to international quality standards and certifications positions it well to compete in the generics and specialty pharmaceuticals sectors. Future outlooks suggest a continued emphasis on innovation, quality manufacturing, and strategic partnerships to drive growth and market penetration.

Brawn Laboratories Limited has a track record of consistent export performance, with a total export value of $22.6 million USD and 673 shipments across 17 products in 10 therapeutic categories. The company's top five products—Enoxaparin, Ciprofloxacin, Syringe, Cephalexin, and Colchicine—account for 62% of its export portfolio, indicating a focused approach to product offerings. The company's adherence to international quality standards and certifications, along with its diversified geographic presence, underscores its reliability as a supplier in the pharmaceutical industry.

Importers should verify the following certifications when considering Brawn Laboratories Limited as a supplier:

• FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S.